NasdaqGS - Delayed Quote • USD
Amgen Inc. (AMGN)
At close: May 17 at 4:00 PM EDT
After hours: May 17 at 7:28 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
29,532,000.00
28,190,000.00
26,323,000.00
25,979,000.00
25,424,000.00
Cost of Revenue
9,931,000.00
8,451,000.00
6,406,000.00
6,454,000.00
6,159,000.00
Gross Profit
19,601,000.00
19,739,000.00
19,917,000.00
19,525,000.00
19,265,000.00
Operating Expense
12,634,000.00
11,842,000.00
10,351,000.00
10,381,000.00
10,126,000.00
Operating Income
6,967,000.00
7,897,000.00
9,566,000.00
9,144,000.00
9,139,000.00
Net Non Operating Interest Income Expense
-3,156,000.00
-2,875,000.00
-1,406,000.00
-1,197,000.00
-1,262,000.00
Other Income Expense
534,000.00
2,833,000.00
-814,000.00
-1,246,000.00
256,000.00
Pretax Income
4,345,000.00
7,855,000.00
7,346,000.00
6,701,000.00
8,133,000.00
Tax Provision
582,000.00
1,138,000.00
794,000.00
808,000.00
869,000.00
Net Income Common Stockholders
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
Diluted NI Available to Com Stockholders
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
Basic EPS
7.03
12.56
12.18
10.34
12.40
Diluted EPS
7.00
12.49
12.11
10.28
12.31
Basic Average Shares
535,500.00
535,000.00
538,000.00
570,000.00
586,000.00
Diluted Average Shares
537,500.00
538,000.00
541,000.00
573,000.00
590,000.00
Total Operating Income as Reported
6,967,000.00
7,897,000.00
9,566,000.00
7,639,000.00
9,139,000.00
Total Expenses
22,565,000.00
20,293,000.00
16,757,000.00
16,835,000.00
16,285,000.00
Net Income from Continuing & Discontinued Operation
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
Normalized Income
3,763,000.00
6,717,000.00
6,552,000.00
7,215,895.00
7,264,000.00
Interest Income
--
--
--
--
256,000.00
Interest Expense
3,156,000.00
2,875,000.00
1,406,000.00
1,197,000.00
1,262,000.00
Net Interest Income
-3,156,000.00
-2,875,000.00
-1,406,000.00
-1,197,000.00
-1,262,000.00
EBIT
7,501,000.00
10,730,000.00
8,752,000.00
7,898,000.00
9,395,000.00
EBITDA
12,071,000.00
14,801,000.00
12,169,000.00
11,296,000.00
12,996,000.00
Reconciled Cost of Revenue
9,931,000.00
8,451,000.00
6,406,000.00
6,454,000.00
6,159,000.00
Reconciled Depreciation
4,570,000.00
4,071,000.00
3,417,000.00
3,398,000.00
3,601,000.00
Net Income from Continuing Operation Net Minority Interest
3,763,000.00
6,717,000.00
6,552,000.00
5,893,000.00
7,264,000.00
Total Unusual Items Excluding Goodwill
--
--
--
-1,505,000.00
--
Total Unusual Items
--
--
--
-1,505,000.00
--
Normalized EBITDA
12,071,000.00
14,801,000.00
12,169,000.00
12,801,000.00
12,996,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
-182,105.00
--
12/31/2020 - 6/17/1983
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRK Merck & Co., Inc.
131.19
+0.24%
ABBV AbbVie Inc.
166.42
+1.26%
LLY Eli Lilly and Company
770.00
-0.15%
GILD Gilead Sciences, Inc.
67.72
-0.21%
BMY Bristol-Myers Squibb Company
44.03
-0.18%
JNJ Johnson & Johnson
154.64
+0.23%
BIIB Biogen Inc.
230.57
+0.23%
PFE Pfizer Inc.
28.64
-0.97%
AZN AstraZeneca PLC
76.90
-0.18%
NVS Novartis AG
102.57
-0.12%